Background: Despite the association with more advanced nodal stage, patients with human papillomavirus (HPV) positive oropharyngeal cancers have better outcomes. We examined whether the HPV can modify the effect of known prognostic factors in tonsillar cancer.
introduction
The incidence of squamous cell carcinoma of the oropharynx in western countries has increased steadily over the past 30 years [1] [2] [3] , and this is due to a rising incidence of human papillomavirus (HPV)-positive cancer [1, 3, 4] . HPV-positive oropharyngeal cancer has distinct clinico-pathological features, and the prognostic significance of HPV status is well established [5] . There is a strong association between HPV positivity, smaller primary cancer stage (T stage) and higher nodal stage (N stage) at diagnosis [5] [6] [7] . Despite the association between HPV and higher nodal stage, patients with HPV-positive oropharyngeal cancer have better outcomes. This raises the possibility that the conventional staging system based on T stage and N stage may not have the same prognostic significance in HPV-positive oropharyngeal cancer.
This study examines whether the HPV status of the tonsillar cancer modifies the effect of prognostic factors (age, gender, grade, T stage and N stage) in tonsillar cancer.
methods study population
The study group comprised 489 patients with tonsillar cancer treated with curative intent at 10 Australian hospitals between 1987 and 2006. The study was approved by the ethics committees of all participating hospitals.
Consecutive patients with accessible cancer material and clinicopathological data were followed up for a median of 3.2 years. Data were retrieved by the review of institutional databases and patient records. The study pathologist reviewed the histology and cancer grade in all cases. Cancers were staged using the American Joint Committee on Cancer staging system.
laboratory studies
An HPV-positive cancer was defined as one testing positive for HPV DNA and with p16 overexpression on immunohistochemistry [8, 9] . The presence and type of HPV DNA were determined by a E6-based multiplex tandem PCR assay (MT-PCR) carried out on two to six 4-5 mm sections of cancer using modifications of the method described by Stanley and Szewezuk [10] as previously described [11] . This assay simultaneously detects and identifies 21 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 82, 53, 6, 11 and 26) . Measured amounts of equine herpesvirus were used to monitor the efficiency of DNA extraction and removal of PCR inhibitors. p16 expression was determined by semi-quantitative immunohistochemistry using the JC2 p16 antibody (Neomarkers, Fremont, CA) as previously described [11] . Staining was strong and diffuse and was essentially all or none. Weak or focal staining was recorded as negative. Immunostaining was evaluated by three independent observers including the study pathologist, all of whom were blinded to the clinical data.
statistical methods
Times to locoregional failure, death with tonsillar cancer and death from any cause were calculated from a patient's date of diagnosis. The KaplanMeier method was used to construct time-to-event curves. For the analysis of time to locoregional failure (defined as clinical, radiological and/or pathological evidence of recurrence at the primary site or in the regional nodal area), patients were censored at last follow-up/death/distal recurrence where applicable. Twenty-six patients (44.4% HPV positive and 55.6% HPV negative) were excluded from this analysis because they had incomplete information on recurrence. For the analysis of time to death with tonsillar cancer, patients were censored at last follow-up/death without tonsillar cancer where applicable, and seven patients were excluded as it was not known if these patients died with or without head and neck cancer. For the analysis of time to death from any cause, patients were censored at last follow-up if they were alive. For disease-specific survival, a second analysis was carried out using a competing risks approach and cumulative incidence curves were produced. Univariate and multivariate time-to-event analyses were undertaken using Cox proportional hazards regression modelling.
results

HPV status and patient characteristics
Two hundred and thirty (47%) of the 489 patients in the study cohort had HPV-positive cancer (HPV DNA positive and p16 positive) and 96% of these were positive for type 16. Other types included 18, 33, 35 and 39. Eight cases of HPV type 16 contained a second HPV type. Eighty-one cases (17%) were HPV DNA positive and p16 negative. This group of patients was included in the HPV-negative group as previously described [5] . Six patients with HPV DNA negative/p16 positive cancers were excluded from the study cohort because it was not known whether the cancers were induced by an HPV type undetectable by the assay or were truly HPV negative ( p16 upregulated through an HPV-unrelated pathway).
Relative to patients with HPV-negative cancer, those with HPV-positive cancer were younger, had lower T stage, and had higher N stage, overall stage and grade cancer (Table 1) .
outcome analyses
Locoregional recurrence occurred in 121 patients as the site of first recurrence. Thirty-five patients developed distant metastasis as the first site of recurrence. At the time of last follow-up, 206 patients had died (124 with tonsillar cancer).
T stage and HPV status were univariate predictors of locoregional recurrence, disease-specific survival and overall survival (supplementary Table S1 , available at Annals of Oncology online). Interaction terms were tested for HPV status and the following patient characteristics: age, gender, T stage, N stage and grade. Evidence of an interaction between HPV original articles
Annals of Oncology status and T stage (P = 0.001, P = 0.02, P = 0.03), and between HPV status and N stage (P = 0.02, P = 0.03, P = 0.01) was found for locoregional recurrence, disease-specific survival and overall survival ( Figure 1A and B, supplementary Figures S1A and B and S2A and B, Table S1 , available at Annals of Oncology online). There was no evidence of any interaction of HPV with age, gender or grade for any of the outcomes (all P > 0.05). The competing risks analysis of disease-specific survival also found significant interactions between HPV status and T stage (P = <0.001) and HPV status and N stage (P = 0.003). Figure S4 , available at Annals of Oncology online). Results generated using a competing risk regression framework were virtually identical to results where times at which competing risks occurred were treated as censored (data not shown).
For HPV-positive cancers, the risk of an adverse outcome tended to increase with respect to T stage, whereas for HPVnegative cancers, the risk did not seem to bear any obvious relation to T stage. The converse was seen for N stage, but perhaps not as clearly. For HPV-positive cancers, the risk of an 
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adverse outcome did not seem to bear any obvious relation to N stage, whereas the risk for HPV-negative cancers tended to increase with respect to N stage.
The multivariate models were refitted treating T and N stage as continuous covariates as part of a sensitivity analysis. Convincing statistical evidence of the T-stage interactions described above was obtained; however, the statistical evidence of the N-stage interactions was weaker (P values for HPV/Nstage interactions for the three outcomes were P = 0.06, P = 0.3 and P = 0.05).
discussion
The conventional staging system for oropharyngeal cancer includes the size and extent of the primary site (T stage) and nodal stage (N stage). The better outcomes in HPV-positive cancers despite the association with higher N stage (therefore higher overall stage) have been well documented in many studies including our own [5, 6, [12] [13] [14] . We focussed our study on patients with carcinoma of the tonsil, the subsite of oropharyngeal cancer with the highest prevalence with HPV positivity to limit the variation in prognosis among the different subsites of the oropharynx [15] . Our results suggest that the prognostic significance of the conventional staging system in tonsillar cancer is modified by HPV status. T stage appeared a more relevant prognostic factor for HPV-positive cancers. There was some evidence that N stage may be a more relevant prognostic factor for HPV-negative cancers; however, precision to model this was affected by the generally small number of events observed for patients with HPV negative, N3 cancers.
Previously Ang et al. proposed a system to classify patients with stage 3 and 4 oropharyngeal cancer into three risk categories according to HPV status, smoking exposure and T or N stage [6] . Patients with HPV-negative oropharyngeal cancer were classified into high risk or immediate risk groups according to T stage and smoking exposure. For patients with HPV-positive cancer, smoking exposure and N stage were used to classify patients into low and immediate risk groups. There are differences between their study cohort and ours. Ang's study was limited to stage 3 and 4 patients, and their patients with HPV-positive cancer did not have a higher nodal stage than patients with HPV-negative cancer as identified by many other studies [5, 7, 13] . We included all stages in our study given the known differential stage distribution at diagnosis in HPV-positive and HPV-negative cancers (lower T stage and higher N stage in HPV-positive cancer) [13, 16] . The retrospective nature of our study limited the availability of reliable smoking and alcohol exposure information. In recent years, the prognostic value of nodal stage in tonsillar cancer has become increasingly controversial [17] [18] [19] [20] . Straetmans et al. studied 81 patients with tonsillar cancer and also suggested that the prognostic value of nodal involvement is reduced by the presence of HPV. The interaction between HPV and N stages could in part explain the inconsistencies in the published data on the prognostic value of N stage in oropharyngeal cancer because some studies did not adjust for the effect of HPV.
The relationship between T stage, N stage and outcome forms the basis of the conventional TNM staging system, which is used to guide treatment and give prognosis. Our results suggest that the conventional TNM staging approach may not be optimal in tonsillar cancer for prognostication given the different prognostic relevance of N stage and T stage for HPV positive versus negative cancers. For patients with HPV-negative tonsillar cancer, nodal stage at diagnosis rather than T stage remains a strong prognostic factor. The relative lack of influence of N stage on outcome in HPV-positive tonsillar cancer suggests that, once treated, an individual's prognosis is not overly affected by N stage. Our results will need to be validated in independent studies before warranting any change to current practice. 
